Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting Oct 20, 2016
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder Sep 21, 2016
Neuralstem Presented NSI-189 Preclinical Data in Type 1 and Type 2 Diabetes at the Annual Meeting of the Diabetic Neuropathy Study Group Sep 12, 2016
Neuralstem Reports Second Quarter 2016 Results and Provides Business and Clinical Updates Aug 11, 2016
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent May 20, 2016
